

<b>Programmi Uso Terapeutico Compassionevole</b>	<b>Promotore</b>	<b>Data Parere Unico CE</b>	<b>Documenti</b>
An Open-label Compassionate Use Study to Evaluate the Safety and Efficacy of VIRAZOLE® (Ribavirin for Inhalation Solution, USP) in Hospitalized Adult Participants with Respiratory Distress Due to SARS-CoV-2 (COVID-19).	Bausch Health	24/04/2020	<a href="https://www.aifa.gov.it/documents/20142/1172315/Ribavirina_documenti.zip">https://www.aifa.gov.it/documents/20142/1172315/Ribavirina_documenti.zip</a>
Programma di Uso Compassionevole con Solnatide per il trattamento dell'edema da permeabilità polmonare in pazienti affetti da COVID-19 con insufficienza polmonare acuta	APEPTICO Forschung und Entwicklung GmbH	15/04/2020	<a href="https://www.aifa.gov.it/documents/20142/1131319/Solnatide_documenti.zip">https://www.aifa.gov.it/documents/20142/1131319/Solnatide_documenti.zip</a>
Managed Access Program (MAP) to provide access to canakinumab treatment of cytokine release syndrome (CRS) in patients with COVID-19-induced pneumonia (CANAKINUMAB, ILARIS)	Novartis	07/04/2020	<a href="https://www.aifa.gov.it/documents/20142/1143282/Canakinumab_documenti.zip">https://www.aifa.gov.it/documents/20142/1143282/Canakinumab_documenti.zip</a>
Ruxolitinib Managed Access Program (MAP) for patients diagnosed with COVID19 and have severe/very severe lung disease (CINC424, RUXOLITINIB, JAKAVI)	Novartis	02/04/2020	<a href="https://www.aifa.gov.it/documents/20142/1140695/Ruxolitinib_documenti.zip">https://www.aifa.gov.it/documents/20142/1140695/Ruxolitinib_documenti.zip</a>
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection. (REMDESIVIR)	Gilead Sciences, Inc	26/03/2020	<a href="https://www.aifa.gov.it/documents/20142/1144520/Remdesivir_documenti.zip">https://www.aifa.gov.it/documents/20142/1144520/Remdesivir_documenti.zip</a>